课题基金 / 基金详情

项目摘要

项目成果

Susmit Suvas的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):单纯疱疹病毒-1(HSV-1)复发可引起多种眼部病理,包括角膜基质中免疫细胞介导的慢性炎症。如果不治疗,角膜基质中的慢性免疫炎症反应可引起疱疹性角膜基质炎(HSK);这是一种导致角膜永久性瘢痕形成的疾病,并且是美国感染诱导的角膜失明的主要原因。目前治疗HSK病变的方法有明显的缺点。因此,迫切需要研究新的方法来控制HSK病变的严重程度。在这项研究中,我们将探讨角膜神经肽,P物质(SP)和血管活性肠肽(VIP),在HSK病变的进展和严重程度在小鼠模型中的作用。我们的长期目标是了解神经肽在调节对HSV-1感染的免疫中的作用。据报道,神经肽SP和VIP在促进或抑制炎症中具有不同的作用。我们的初步研究表明,与轻度HSK病变相比,重度HSK病变小鼠角膜中SP含量较高,但VIP水平较低。因此,我们推测炎症角膜中的神经肽SP和VIP调节HSK病变的进展和严重程度。HSK病变的发展是免疫介导的,涉及促炎细胞因子(IL-1、IL-6、IL-2、IFN-3和TNF-1)、趋化因子(MIP-1和MIP-2)和免疫细胞类型如中性粒细胞和CD 4 T细胞。因此,我们将通过证明角膜神经肽SP和VIP调节HSV-1感染角膜中促炎和抗炎细胞因子和趋化因子的量来测试我们的假设。我们还将证明SP和VIP调节病毒感染角膜中中性粒细胞和CD 4 T细胞的流入、存活和效应功能。我们预计,我们的研究结果将提供一种新的方法来阐明HSK的发病机制,并可能显着影响这种情况的管理。 公共卫生相关性:角膜的复发性单纯疱疹病毒1型(HSV-1)感染导致疱疹性角膜基质炎(HSK)的发展,这是一种可导致永久性瘢痕形成和视力丧失的疾病。目前控制HSK的疗法具有显著的缺点。在这项研究中,我们将通过了解角膜神经肽在HSK进展和严重程度中的作用,研究一种新的方法来管理小鼠模型中的HSK。
英文摘要
DESCRIPTION (provided by applicant): Herpes simplex virus-1 (HSV-1) recurrences can cause many ocular pathologies including, immune cell mediated chronic inflammation in the corneal stroma. If left untreated, the chronic immunoinflammatory reactions in the corneal stroma can give rise to herpetic stromal keratitis (HSK); a disease that results in permanent scarring of the cornea and is a leading cause of infection induced corneal blindness in the United States. The current therapies to manage the HSK lesions have significant downsides. Therefore, investigating novel approaches to control the severity of HSK lesions are urgently needed. In this study, we will explore the role of corneal neuropeptides, substance P (SP) and vasoactive intestinal peptide (VIP), in the progression and severity of HSK lesions in a mouse model. Our long-term goal is to understand the role of neuropeptides in regulating the immunity to HSV-1 infection. Neuropeptides SP and VIP are reported to have differential roles in promoting or inhibiting the inflammation. Our pilot studies demonstrated higher amounts of SP but lower levels of VIP in the mice corneas with severe HSK lesions in comparison to those with mild HSK lesions. Therefore, we hypothesize that neuropeptides SP and VIP in the inflamed cornea regulate the progression and severity of HSK lesions. The development of HSK lesions is immune-mediated, with the involvement of pro-inflammatory cytokines (IL-1, IL-6, IL-2, IFN-3 and TNF-1), chemokines (MIP-1 and MIP-2), and immune cell types such as neutrophils and CD4 T cells. Therefore, we will test our hypothesis by demonstrating that corneal neuropeptides SP and VIP regulate the amounts of pro- and anti-inflammatory cytokines, and chemokines in HSV-1 infected corneas. We will also demonstrate that SP and VIP regulate the influx, survival and effector function of neutrophils and CD4 T cells in virus infected corneas. We anticipate that our findings will provide a novel approach to elucidate the pathogenesis of HSK and may significantly impact the management of this condition. PUBLIC HEALTH RELEVANCE: Recurrent herpes simplex virus type-1 (HSV-1) infection of the cornea results in the development of herpetic stromal keratitis (HSK), a disease that can cause permanent scarring and loss of vision. The current therapies to control HSK have significant drawbacks. In this study, we will investigate a novel approach to manage HSK in a mouse model by understanding the role of corneal neuropeptides in the progression and severity of HSK.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CXCR4: A potential therapeutic target in HSK
  • 批准号:
    10752865
  • 项目类别:
  • 资助金额:
    $38.5万
  • 财政年份:
    2023
  • 负责人:
    Susmit Suvas
  • 依托单位:
Role of insulin-like growth factor binding proteins in the pathogenesis of herpes stromal keratitis.
  • 批准号:
    10468069
  • 项目类别:
  • 资助金额:
    $36.34万
  • 财政年份:
    2020
  • 负责人:
    Susmit Suvas
  • 依托单位:
Role of insulin-like growth factor binding proteins in the pathogenesis of herpes stromal keratitis.
  • 批准号:
    10056782
  • 项目类别:
  • 资助金额:
    $37.74万
  • 财政年份:
    2020
  • 负责人:
    Susmit Suvas
  • 依托单位:
Role of insulin-like growth factor binding proteins in the pathogenesis of herpes stromal keratitis.
  • 批准号:
    10219263
  • 项目类别:
  • 资助金额:
    $36.34万
  • 财政年份:
    2020
  • 负责人:
    Susmit Suvas
  • 依托单位:
海外基金